人口统计学 |
|
Patients |
105 |
男性 |
66 (63) |
Age at lung transplantation years |
31.4(20.5-43.5) |
Patients <18 years |
18(17) |
Never-smoker |
88(84) |
FEV1%预计 |
18(15-21) |
FVC % pred |
35 (25-48) |
TLC % pred# |
103(74-119) |
Restrictive GvHD phenotype |
51(49) |
Airway colonisation |
39(37) |
Pseudomonas aeruginosa |
20(19) |
Aspergillus fumigatus |
8(8) |
eGFR (CKD-EPI) mL·min-1·1.73 m-2 |
93.1(84.5-119.3) |
SCT |
|
Indication |
|
Acute myeloid leukaemia |
38(36) |
Acute lymphoblastic leukaemia |
16(15) |
Chronic myeloid leukaemia |
18(17) |
Chronic lymphocytic leukaemia |
2(2) |
Non-Hodgkin lymphoma |
6(6) |
Hodgkin lymphoma |
6(6) |
Myelodysplastic syndrome |
图7(7) |
Nonmalignant disease |
12(11) |
Type |
|
Bone marrow |
51(49) |
外周血 |
54(51) |
Age at first SCT years |
22.7(14.4-36.3) |
>1 SCT attempt |
6(6) |
Timing of SCT after diagnosis months |
11.2(4.5-21.0) |
调节治疗 |
|
降低强度 |
16(18) |
Myeloablative |
87(83) |
Busulphan |
32(35) |
Cyclophosphamide |
47(52) |
Fludarabine |
20(22) |
Melphalan |
17(19) |
Total body irradiation¶ |
46 (53) |
的GvHD |
|
肺外任何部位的参与 |
74(70) |
皮肤 |
52(49) |
胃肠道 |
31日(30) |
目镜 |
33(31) |
粘膜 |
43(41) |
肺外网站n |
2(0-3) |
Treatment |
|
环孢素 |
75(71) |
Steroid |
68(65) |
Mycophenolate |
31日(30) |
Methotrexate |
18(17) |
GvHD在肺移植中的治疗 |
2(2-3) |
肺移植 |
|
双边肺移植 |
89(85) |
Timing of lung transplantation after SCT months |
69 (36 - 122) |
Lung transplantation <2 years post-SCT |
15(14) |
Induction |
35(33) |
Inpatient |
38(36) |
重症监护 |
23(22) |
Mechanical ventilation only |
14(13) |
ECMO only |
5(5) |
机械通风与ECMO相结合 |
4(4) |
Inpatient stay post-lung transplantation days |
37(23-71) |
Patient follow-up post-lung transplantation months |
34(9-75) |